Takeda will jointly work with Fujifilm on regenerative medicine therapies

| By | Drug Development, R&D, Stem Cells

FUJIFILM Corporation  and Takeda Pharmaceutical Company Ltd., announced a collaboration to develop regenerative medicine therapies using cardiomyocytes derived from Induced Pluripotent Stem Cells (iPSC) for the treatment of heart failure.

Collaborative research will combine Fujifilm’s expertise in cutting-edge iPSC-related technologies and engineering technology nurtured by photographic business with Takeda’s iPSC technology capabilities. This will be fostered by collaborative research with Center for iPS Cell Research and Application at Kyoto University (CiRA), as well as expertise in pre-clinical and clinical studies for drug development to make effective and safe therapies available for cardiac patients.

“We are delighted to initiate this partnership applying practical use of our iPSC-derived cardiac cells with Takeda, which has abundant experience in drug development and clinical trials,” said Aiichiro Hiruma, General Manager of Regenerative Medicine Division at FUJIFILM Corporation. “In addition to establishing new treatment methods for patients with heart disease, Fujifilm and Takeda will contribute to the elevation of regenerative medication business to the industrial stage by applying our engineering technologies to manufacture high-quality cells safely and efficiently.”

SOURCE: takeda
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.